Ketorolac 0.5% eyedrops — Competitive Intelligence Brief

Ketorolac 0.5% eyedrops (Ketorolac 0.5% eyedrops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Ophthalmology Small molecule

Target snapshot

Ketorolac 0.5% eyedrops (Ketorolac 0.5% eyedrops) — Università degli Studi di Brescia. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketorolac 0.5% eyedrops TARGET	Ketorolac 0.5% eyedrops	Università degli Studi di Brescia	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Aspirin loading dose	Aspirin loading dose	Icahn School of Medicine at Mount Sinai	marketed	Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Novel strategy Aspirin	Novel strategy Aspirin	Assistance Publique - Hôpitaux de Paris	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Active ASA	Active ASA	Hamilton Health Sciences Corporation	marketed	Nonsteroidal Anti-Inflammatory Drug (NSAID)	Cyclooxygenase (COX) enzymes
Diclofenac oral + Placebo Oral	Diclofenac oral + Placebo Oral	Hospital de Clinicas de Porto Alegre	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
ketorolac (Acular LS)	ketorolac (Acular LS)	Center For Excellence In Eye Care	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Ketorolac Tromethamine Injection	Ketorolac Tromethamine Injection	UConn Health	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class